Terumo Neuro
Gabrielle Ahad is an experienced engineer currently serving as an Engineer II in the Research and Development team at MicroVention-Terumo since August 2022, where responsibilities include new product development, technical documentation, process testing, and prototype design. Previous roles at MicroVention-Terumo included Engineer I in both R&D and Manufacturing, focusing on process improvement and validation. Gabrielle has held leadership roles in the Quality of Life Plus Program, where innovative projects aimed to improve the lives of individuals with disabilities, and participated in the Lavin Entrepreneur Program, promoting interdisciplinary collaboration among budding entrepreneurs. Other experience includes an intern role in Business Excellence, research in the Cardiovascular Bioengineering Lab at San Diego State University, and various positions in quality assurance and manufacturing. Gabrielle holds a Bachelor's degree in Mechanical Engineering/Bioengineering from San Diego State University.
Terumo Neuro
1 followers
A global leader in neurovascular innovation, MicroVention is now Terumo Neuro. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care. We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica.